Anti-Factor Bb Antibodies Selective Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective methods to inhibit inappropriate activation of the alternative complement pathway, which can lead to tissue damage and various pathological conditions, without disrupting the classical pathway's immune defense functions.
Innovation Solution
Development of anti-factor Bb antibodies that selectively inhibit the formation of C3a, C5a, and C5b-9 by binding to the Bb motif of Factor B, preventing the activity of C3bBb or C5b-9 complexes without interfering with Factor B's binding to C3b, thereby reducing inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-factor Bb antibodies are used to inhibit alternative pathway activation, then inflammatory responses and tissue damage are reduced, but the risk of compromising immune defense functions increases
Solution Approach 1:
The invention targets a specific segment (factor Bb) within the larger factor B protein, which is a component of the alternative pathway but not the classical pathway. By selectively inhibiting factor Bb through anti-factor Bb antibodies, the patent segments the complement system's functionality, allowing suppression of the alternative pathway's harmful inflammatory effects while preserving the classical pathway's immune defense capabilities.
Solution Approach 2:
The patent applies local quality by creating selective inhibition at a specific location in the complement cascade. The anti-factor Bb antibodies bind specifically to factor Bb, creating a localized blocking effect that prevents C3bBb complex formation and alternative pathway activation only where factor Bb is present, without affecting other pathways or functions.
2Object-affected harmful factors
If factor B binding to C3b is inhibited, then alternative pathway activation is blocked, but the binding interaction itself is disrupted
Solution Approach 1:
The invention extracts or removes factor Bb from the functional complex by binding it with high affinity antibodies. The anti-factor Bb antibodies specifically capture factor Bb, preventing it from binding to C3b and forming the C3bBb convertase complex, thereby extracting the harmful element from the activation pathway without disrupting the overall structural integrity of the complement system.
Solution Approach 2:
The anti-factor Bb antibodies act as intermediary molecules that bind to factor Bb and prevent its interaction with C3b. These antibodies serve as a mediating block between factor Bb and C3b, allowing the system to maintain the binding site integrity while preventing the harmful binding interaction that leads to alternative pathway activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-factor Bb antibodies effectively reduce the adverse effects of alternative complement pathway activation, such as inflammation and tissue damage, while maintaining the integrity of the classical pathway for immune defense, thereby treating conditions like atherosclerosis, rheumatoid arthritis, and other inflammatory disorders.
Implementation Method 1
anti-factor Bb antibodies that selectively inhibit the formation of C3a, C5a, and C5b-9 by binding to the Bb motif of Factor B
Data Source
AI summary
A pharmaceutical composition includes an isolated anti-Bb antibody or antigen binding portion thereof produced by a hybridoma cell line deposited under ATCC Accession Number PTA-8543 or an isolated anti-Bb antibody or antigen binding portion thereof that competitively inhibits binding of the antibody or antigen binding portion produced by the hybridoma cell line deposited under ATCC Accession Number PTA-8543 to the Bb segment of factor B; and a pharmaceutically acceptable carrier.